Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients
T Müller, W Kuhn - European journal of clinical pharmacology, 2006 - Springer
Background Elevated plasma total homocysteine (tHcy) appeared in levodopa/
dopadecarcoxylase inhibitor (DDI) treated patients with Parkinson's disease (PD). One …
dopadecarcoxylase inhibitor (DDI) treated patients with Parkinson's disease (PD). One …
[HTML][HTML] L-serine: Neurological Implications and Therapeutic Potential
SMM Phone Myint, LY Sun - Biomedicines, 2023 - mdpi.com
L-serine is a non-essential amino acid that plays a vital role in protein synthesis, cell
proliferation, development, and sphingolipid formation in the central nervous system. It …
proliferation, development, and sphingolipid formation in the central nervous system. It …
[HTML][HTML] Lithium ascorbate as a promising neuroprotector: fundamental and experimental studies of an organic lithium salt
IY Torshin, OA Gromova, KS Ostrenko, MV Filimonova… - Molecules, 2022 - mdpi.com
Given the observable toxicity of lithium carbonate, neuropharmacology requires effective
and non-toxic lithium salts. In particular, these salts can be employed as neuroprotective …
and non-toxic lithium salts. In particular, these salts can be employed as neuroprotective …
Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man
A Leusch, W Troger, A Greischel, W Roth - Xenobiotica, 2000 - Taylor & Francis
1. Talsaclidine is an M1-agonist under development for the treatment of Alzheimer's disease.
The aim of the study was to investigate the absorption, distribution, metabolism and …
The aim of the study was to investigate the absorption, distribution, metabolism and …
Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC–MS/MS
Loxapine represents an interesting example of old “new” drug and is recently drawing
attention for its novel inhalation formulation for the treatment of both psychiatric and non …
attention for its novel inhalation formulation for the treatment of both psychiatric and non …
Current status of safinamide for the drug portfolio of Parkinson's disease therapy
T Müller - Expert Review of Neurotherapeutics, 2013 - Taylor & Francis
Parkinson's disease (PD) is characterized by a slowly ongoing neuronal death. This alters
dopaminergic and glutamatergic neurotransmission and causes a wide variety of motor and …
dopaminergic and glutamatergic neurotransmission and causes a wide variety of motor and …
Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence
Salvinorin A (SA) is a potent kappa opioid agonist with a brief duration of action. Consistent
with this, our previous positron emission tomography (PET) studies of carbon-11 labeled SA …
with this, our previous positron emission tomography (PET) studies of carbon-11 labeled SA …
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen
ZS Teksin, IJ Lee, NN Nemieboka, AA Othman… - European Journal of …, 2009 - Elsevier
Salvinorin A is an unregulated potent hallucinogen isolated from the leaves of Salvia
divinorum. It is the only known non-nitrogenous kappa-opioid selective agonist, and rivals …
divinorum. It is the only known non-nitrogenous kappa-opioid selective agonist, and rivals …
Precise GC/MS assays for salsolinol and tetrahydropapaveroline: the question of artifacts and dietary sources and the influence of alcohol.
GA Smythe, MW Duncan - Progress in clinical and biological …, 1985 - europepmc.org
The use of GC/MS with appropriate deuterated internal standards has enabled the
development of highly precise assays for salsolinol and THP. The deuterated standards we …
development of highly precise assays for salsolinol and THP. The deuterated standards we …